Sharing personal experience on the development of cell therapy technology, quality & analytics since the 1990s & the application of ‘phase appropriate GMPs’ to cell therapy development

David McCall, Commissioning Editor, BioInsights, spoke to Amnon Eylath, VP Head of Global Quality, Minovia Therapeutics

Amnon Eylath is a seasoned Quality Leader, experienced in the life cycle of Small molecule, and Biotech drug development, including R&D through nonclinical and GLP Tox studies, clinical trials, process and method development, manufacturing, validation, regulatory submissions for clinical trials and US/EU product approvals, to global distribution of commercial products. Direct experience with Therapeutic Monoclonal Antibodies, Cell and Gene Therapy. Led/supported cross-functional Continuous Improvement & Gap-Remediation initiatives at multiple companies. Implemented multiple electronic QMS systems at small and large companies. Initiated Amgen’s Lean-Six Sigma program and Black Belt. Presented at PDA and ISPE events on multiple subjects, including Cost-Effective Validation, Sanitization using Chlorine Dioxide Gas, and more. Active speaker on Qualistery – GXP educational web-seminars. Member and volunteer at the PDA since 1996, leading the TR-56 technical report task force on Phase Appropriate Application of Quality Systems and GMP, co-author on TR-65 Technology Transfer (version 1.0). Past President of the New England Chapter of the PDA, supporting the New England BioPharma community and the Middlesex community College Biotechnology certificate/degree program and NEPDA scholarship awards. Member of the MSCC Biotechnology Program Advisory Board and founding member of the Northeastern University Biotechnology Program Advisory Board.

Please enter your email to access content Read now